LIN28A and epilepsy: Finally, we confirmed that HTR4 immunoreactivity was observed in LIN28A-expressing cells in SGZ at 3 days after SE (Figure 7F), suggesting that HTR4 can be a potential LIN28A-downstream target in epilepsy.